business
Pipeline
Autologous Immunotherapy
SNK01-US01 Clinical study in the U.S.
- Target disease : Combination Therapy of Refractory Cancer + Pembrolizumab or Avelumab
- Trial No. : NCT03941262 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
SNK01-N12a Clinical study in Korea
- Target disease : Combination therapy of non-small cell lung cancer + pembrolizumab
- Trial No. : KCT0003463 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
SNK01-TRN12a Clinical study in Korea
- Target disease : Combination therapy of non-small cell lung cancer + Chemotherapy or Cetuximab
- Trial No. : NCT04872634 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
SNK01-AFM24 Clinical study in the U.S.
- Target disease : Combination Therapy of EGFR-positive Cancer + AFM24
- Trial No. : NCT05099549 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
SNK01-MX03 Clinical study in Mexico
- Target disease : Psoriasis (autoimmune disease)
- Trial No. : NCT03894579 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
SNK01-MX04 Clinical study in Mexico
- Target disease : Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD)
- Discovery
- Preclinical
- Phase I
- Phase II
Allogenic Immunotherapy
- Discovery
- Preclinical
- Phase I
- Phase II
CAR-NK
- Discovery
- Preclinical
- Phase I
- Phase II